Shares of biopharmaceutical company Hookipa Pharma (NASDAQ:HOOK) are soaring today on the back of its licensing deal with Roche for HB-700 and a novel immunotherapy (undisclosed).
Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
With this move, Hookipa gains an upfront payment of $25 million, a potential optional payment of $15 million for another candidate as well as milestone payments of up to $930 million (apart from sales royalties).
Shares are now up ~24.4% over the last five days.
Read full Disclosure